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Testicular germ cell tumours (TGCTs) are the most common cause of cancer in men between the ages of 15 and 40 years, and,
overall, the majority of patients should expect to be cured. The European Germ Cell Cancer Consensus Group has provided clear
guidelines for the primary treatment of both seminoma and nonseminomatous germ cell tumours. There is, however, no international
consensus on how best to follow patients after their initial management. This must promptly and reliably identify relapses without
causing further harm. The standardising of follow-up would result in optimising risk-benefit ratios for individual patients, while ensuring
economic use of resources. We have identified the seven common scenarios in managing seminomas and nonseminomas of the
various stages and discuss the pertinent issues around relapse and follow-up. We review the available literature and present our
comprehensive TGCT follow-up guidelines. Our protocols provide a pragmatic, easily accessible user-friendly basis for other centres
to use or to adapt to suit their needs. Furthermore, this should enable future trials to address specific issues around follow-up giving
meaningful and useful results.
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Background
Testicular germ cell tumours (TGCTs) are uncommon malignan-
cies but the most common cause of cancer in men between the ages
of 15 and 40 years. The peak incidence for nonseminomatous germ
cell tumour (NSGCT) is between 20 and 30 years of age, and for
seminoma between 30 and 40 years. In the United Kingdom, the
incidence rate is only 1:100000 men per year with a lifetime risk
of developing a TGCT of 1 in 400 and 1900 new cases per year
(Horwich, 2002). There has, however, been a steady increase in the
incidence of TGCTs in European countries in the last two decades
(Bergstrom et al, 1996). The reasons for this increasing incidence
and the aetiology of TGCTs remain unknown. The European Germ
Cell Cancer Consensus Group has provided clear guidelines for the
primary treatment of both seminoma tumour and NSGCT
(Schmoll et al, 2004). There is, however, a lack of clear consensus
on how to follow patients after primary treatment, and a number of
issues dictate that follow-up should be carefully thought out and
rigorously adhered to. Here, we discuss these factors as they
pertain to male germ cell tumour (GCT) practice and describe our
recently developed protocols.
Rational for follow-up
Detecting relapse In general, detecting relapse is the major reason
for maintaining follow-up and is the main focus of this review. The
management of testicular cancer has been a major oncological
success story, and provides a model for the management of
curative solid tumours (Horwich et al, 2006). The use of platinum-
based chemotherapy schedules has resulted in high cure rates for
all stages of the disease (International Germ Cell Cancer
Collaborative Group, 1997). The fact that the majority of young
men treated for testicular cancer have a durable response to
primary treatment has resulted in the accumulation of significant
data on both the patterns of relapse and the late effects of
treatment. Lifelong cure rates are high but there remains a tangible
risk of relapse. These relapses may be salvageable with a
combination of further chemotherapy and surgery; recent studies
suggest that around 50% of patients who relapse after primary
treatment will be cured, depending on the pattern of relapse and
the stage at detection (Fossa et al, 1999b; Huddart and Birtle,
2005). It is also recognised that late relapses (occurring greater
than 2 years after complete remission) have a greater propensity
for chemoresistance and confer a worse prognosis (Shahidi et al,
2002; Ronnen et al, 2005). The fact that relapses are discernable
through the use of serum tumour markers and/or radiological
imaging confers a responsibility for their prompt detection.
However, false-negative computerised tomography (CT) examina-
tions can occur owing to the inability of this modality to detect foci
of disease in normal-sized nodes or to differentiate benign and
malignant enlargement. It has been shown that by using 10–
15mm as the upper limit of normal, up to 44% of scans were false
negative (Thomas et al, 1981; Richie et al, 1982; Rowland et al,
1982). For practical purposes then, a cutoff of 10mm is used
Received 15 November 2007; revised 14 December 2007; accepted 4
January 2008; published online 10 June 2008
*Correspondence: Dr RA Huddart, Royal Marsden Hospital, Orchard
House, Downs Road, Sutton SM2 5PT, UK;
E-mail: Robert.Huddart@icr.ac.uk
British Journal of Cancer (2008) 98, 1894–1902
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
streating those measuring between 8 and 10mm as suspicious.
These measurements should be taken in the overall context of the
patient (risk of disease, markers and tumour laterality) (Dalal et al,
2006). Tumour markers (bHCG and/or AFP) are elevated at relapse
in about 2/3 of NSGCT and approximately 1/3 of seminomas.
While LDH is vital in prognostication of metastatic disease and
thus should be routinely included, its use in detecting relapse is
questionable (Ackers and Rustin, 2006; Venkitaraman et al, 2007).
Although markers may act as useful flags for relapse, they do not
remove the need for clinical and imaging assessment in view of the
rate of marker-negative relapse.
Detection of second primary cancer A separate issue is that of
metachronous, contralateral primary testicular tumours. Although
a number of studies have reported an increased incidence, in the
absence of specific risk factors (testicular maldescent, infertility,
atrophy, young age at first presentation and microlithiasis;
Harland et al, 1998; Holm et al, 2003) this risk is still low with a
15-year cumulative incidence of just 1.9% (Fossa et al, 2005). Apart
from being encouraged to perform routine self-examination, we
would not, therefore, routinely perform contralateral biopsies as part
of our follow-up. The major risk factor for second primary cancer is
thought to be testicular atrophy (Harland et al, 1998). Thus, in
patients with a testicular volume of o12ml, we would discuss the
role of testicular biopsy to detect carcinoma in situ (before or at least
2 years post chemotherapy). If detected, carcinoma in situ is
managed appropriately (Hoei-Hansen et al, 2004).
Late effects: physical A third potential reason for undertaking
follow-up is to assess, monitor and manage late toxicity of
treatment. In addition to the well-recognised acute side effects of
chemotherapy the significance of late side effects have become
increasingly appreciated. Long-term survivors of testicular cancer
may display an increased risk of cardiovascular disease (Huddart
et al, 2003; Huddart and Birtle, 2005; van den Belt-Dusebout et al,
2006) and second malignancy (Travis et al, 2005; Raghavan et al,
2006). Other problems identified include long-term sensory
neuropathy, Raynaud’s phenomenon (Fossa, 2004) and effects on
fertility (Brydoy et al, 2005; Huddart et al, 2005). Development of
‘metabolic syndrome’ and other long-term endocrine disturbance
is also recognised (Nuver et al, 2005; Horwich et al, 2006). To date,
detection and management of toxicity have been a minor
component of most oncologists practice, and, in the main, this
aspect has, by default, been delegated to primary care. Raghavan
has made some recommendations but the evidence base for
making recommendations in this area is limited. Detailed
discussion of these issues is beyond the scope of this review,
although we have made some rudimentary suggestions for late
effect monitoring.
Late effects: psychological A proportion of testicular cancer
patients are psychologically vulnerable and find the diagnosis of
testicular cancer traumatic. Subsequent treatment may signifi-
cantly affect sexual function, cause anxiety, disrupt ability to work
and reduce overall quality of life (Fleer et al, 2006; Dahl et al, 2007;
Tuinman et al, 2007). Follow-up can help support such patients
and help to rehabilitate so that they return to normal life.
Research Research is rarely the major goal of follow-up, but the
long-term follow-up of patients and collection of data within
prospective trials and cohort-based databases have undoubtedly
contributed significantly to understanding testicular cancer and
treatment outcomes.
Risks of radiological intervention
Repeated use of imaging techniques that utilise ionising radiation
(specifically chest radiographs and CT scanning of the thorax,
abdomen and pelvis) is associated with a measurable risk of
causing second malignancies. These risks must be outweighed by
demonstrable benefit to patients (Hoffman et al, 1989; Boice et al,
1991; Brenner, 2004; Ronckers et al, 2005). Thoracic CT requires a
radiation dose equivalent to 400 chest radiographs (8 vs 0.02mSv),
increasing the exposure to 20mSv if the abdomen is included. It
has been suggested that this results in a 1:1000 lifetime risk of
second cancer/leukaemia over the subsequent 40 years (Dalal et al,
2006). A chest X-ray is a low-cost low-risk procedure, which is
likely to pick up nodules of 1cm or greater in the lungs, pleurally
based lesions or mediastinal masses (Dalal et al, 2006).
General principles
Throughout these recommendations, we have considered the
following data on imaging. The chest can be imaged both by chest
X-ray and CT of the chest but thoracic relapse in nonseminomatous
(NS) will for the most part be marker positive, and the great majority
of GCTs that relapse will have significant disease burden outside the
chest (Gietema et al, 2002; Oldenburg et al, 2006; Martin et al, 2007).
Computerised tomography chest may pick up small marker-negative
lesions not visible on chest X-ray, but unless the detection of such
small lesions is likely to have prognostic significance, we omit chest
CT from our follow-up schedules due to the significant additional
radiation exposure. Although one study suggests no additional
benefit to using chest X-ray, we feel that if CT of the chest is omitted
it is worth performing a chest X-ray (Gietema et al,2 0 0 2 ) .W h i l e
pelvic CT forms an integral part of initial staging, there is minimal
value in routinely scanning the pelvis as part of the follow-up. While
there is no firm evidence base, there is a perceived increased risk of
pelvic lymph node disease following scrotal interference, and, for this
reason, we include a pelvic CT in this setting (White et al, 1997).
For each clinical scenario, we have reviewed the frequency and
time to relapse both from the published literature and our own
experience, and defined the frequency and nature of the follow-up
according to principles previously outlined (Appendix A). We have
graded the evidence and recommendations according to the
guidelines set out by the American Society of Clinical Oncology
(Appendix B) and these are given in square brackets. Recommen-
dations without grading were based on the extensive clinical
experience of clinicians from the Royal Marsden Hospital.
SEMINOMA
Stage I
Approximately, 75% of men who are diagnosed with seminoma
have stage I disease, for which management options following
orchidectomy consist of surveillance or adjuvant treatment in the
form of either radiotherapy or, more recently, a single cycle of
carboplatin chemotherapy (Oliver et al, 2005). The disease-specific
survival for stage I disease approaches 99% independent of the
management strategy used (Oldenburg et al, 2006).
Seminoma stage I surveillance Eighty per cent of patients with
stage I seminoma will be cured with orchidectomy alone,
suggesting that only 20% of patients might benefit from adjuvant
treatment. The identification of tumour size greater than 4cm and
rete-testis invasion as prognostic factors, has allowed further risk
stratification of this group of patients. If neither risk factor is
present, then the risk of relapse is less than 12%, this increases to
15% if one factor is present and over 30% if both are present
(Warde et al, 2002). We consider patients with none or one risk
factor as ideal candidates for surveillance, and, in those with both
risk factors, we feel that there is a stronger argument for adjuvant
treatment. However, as patients who relapse on surveillance are
routinely cured with subsequent treatment, surveillance can be
Guidelines for the follow-up of testicular cancer
NJ van As et al
1895
British Journal of Cancer (2008) 98(12), 1894–1902 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sconsidered as an option for all patients with stage I disease. The
overall crude relapse rate for patients managed with surveillance is
15.2–19.3% (Chung et al, 2002; Warde et al, 2002; Choo et al, 2005;
Oldenburg et al, 2006). Most relapses occur in the first 2 years with
a 45% annual hazard rate (AHR); relapses after 2 years are rare
but are reported to occur up to 6 years after initial diagnosis
(Warde et al, 2002; Oldenburg et al, 2006). The majority of relapses
are in the para-aortic nodes, followed by mediastinal, supraclavi-
cular nodes and lung metastasis (Dieckmann et al, 2005;
Oldenburg et al, 2006). Note that only 30% of seminoma relapses
will be marker positive. No studies have addressed the optimal
scanning or follow-up frequency with widely differing policies
reported (Huddart and Joffe, 2006). We suggest 3 monthly clinic
visits and markers with 6 monthly CT scans of the abdomen and a
chest X-ray for the first 2 years, based on need for regular cross-
sectional imaging in the highest risk period [III, B]. The pelvis
should only be scanned if there has been scrotal interference or
previous pelvic surgery [III, B]. Follow-up should reduce to 4
monthly in year 3 and then 6 monthly until year 5. Computerised
tomography scans and chest X-rays are performed annually until
year 5 [III, B]. Annual follow-up with clinical examination and
markers should continue for a further 5 years prior to discharge
[III, B].
Seminoma stage I adjuvant radiotherapy follow-up Historically,
adjuvant treatment has taken the form of radiotherapy resulting in
cure rates of 97–100%. Following two MRC trials investigating
field and dose (Fossa et al, 1999a; Jones et al, 2005), the current
European recommended schedule for adjuvant radiotherapy is
20Gy in 10 fractions to the para-aortic nodes. Relapses in the
treatment field are extremely uncommon; however, when the
pelvic field is omitted, there is a small but statistically higher rate
of pelvic relapse (Fossa et al, 1999a). In a combined review of 1535
patients treated with para-aortic radiotherapy, the relapse rate at 5
years was 3.6%, with 0.3% of relapses occurring in the abdomen
(Martin et al, 2007). Most relapses occur in the first 2 years. The
annual hazard ratio from the largest reported series for relapse
between 2 to 6 years is 0.25–1% (Martin et al, 2007). For patients
treated with para-aortic radiotherapy, we suggest 3 monthly
clinical examination and markers for the first year and 4 monthly
for the second year, and then 6 monthly until 5 years [III, B].
Computerised tomography scans of the pelvis only (unless a
clinical reason exists to scan abdomen) performed annually for the
first 2 years and then at 5 years prior to discharge [IV, C]. The
value of pelvic CT is unclear. One publication on omitting pelvic
CT reported satisfactory overall outcomes, but a number of
patients presented with large symptomatic pelvic masses (Livsey
et al, 2001). A chest X-ray should be performed at 3 and 6 months
and then annually until discharge. The extremely low risk of
relapse after 5 years (approaching 0%), makes follow-up beyond 5
years unnecessary (Shahidi et al, 2002) [III, B].
Seminoma stage I follow-up after single-agent carboplatin An
alternative adjuvant treatment to radiotherapy is a single cycle of
carboplatin chemotherapy. The use of a single cycle of carboplatin
has been investigated by a number of groups (Dieckmann et al,
2000; Oliver et al, 2005). Most notably, Oliver et al reported a
randomised trial of 1477 patients demonstrating no inferiority of a
single cycle of carboplatin as compared with para-aortic radio-
therapy with respect to disease-free and overall survival. The trial
has only reported 4-year follow-up data and although there are
limited data on risk of late relapse and on long-term toxicity, in
many UK centres the use of carboplatin for stage I seminoma now
exceeds the use of radiotherapy. Five-year relapse rates for a single
cycle of carboplatin are 6.1% with more than 80% of relapses
occurring in the abdomen (Martin et al, 2007) (in contrast to
patients treated with para-aortic radiotherapy where abdominal
relapses are extremely uncommon). We, therefore, recommend CT
scan of the abdomen and a chest X-ray yearly, for the first 2 years
and again at 5 years; the pelvis should only be scanned if there has
been scrotal interference or previous pelvic surgery [III, B].
Patients should have a clinical examination and markers at 1
month after chemotherapy, and then 3 monthly for the first year, 4
monthly for the second year and then 6 monthly until year 5. Data
on late relapses in the carboplatin-treated patients are not yet
available, and, for this reason, it is recommended that these
patients should also be followed for 10 years.
Stages IIa/b
Stage IIa seminoma includes patients with para-aortic lymph
nodes up to 2cm in size. Stage IIb disease includes those with
nodes 2–5cm. There is considerable variability on how stage IIa/b
seminomas are treated. The treatment options for stage IIa/b
seminomas include, para-aortic and iliac node radiotherapy
(Schmidberger et al, 1997; Warde et al, 1998; Classen et al, 2003;
Chung et al, 2004), three cycles of BEP (bleomycin, etoposide and
cisplatin) or four cycles of EP (etoposide and cisplatin)
chemotherapy or a combination of carboplatin chemotherapy
and para-aortic radiotherapy (Warde et al, 1998; Arranz Arija et al,
2001; Patterson et al, 2001). All three of the above options provide
high rates of cure, but with differing toxicity profiles. Patients
treated with chemotherapy alone should be followed according to
Stage IIc–IV Guidelines, but we present our protocol for follow-up
post-combination carboplatin radiotherapy.
Stage IIa/b (post chemoradiotherapy) follow-up Data obtained
from the trials of a single cycle of carboplatin in stage I seminoma
suggest that this treatment is sufficient to eradicate microscopic
disease in the great majority of patients. We know that radio-
therapy is highly effective in eradicating disease with up to 5cm in
size in the para-aortic nodes (Classen et al, 2003; Chung et al,
2004). Our current protocol for treating patients with stage IIa/b
disease, is to give one cycle of carboplatin (AUC 7) followed 4
weeks later by para-aortic radiotherapy to a dose of 30Gy in 15
fractions based on 5-year relapse-free survival probability of 96.9%
(Patterson et al, 2001) achieved at our institution. We suggest
3-monthly clinic examinations and markers for the first year, 4
monthly for the second year, 6 monthly until year 5 and then
annual review. Computerised tomography scan of the pelvis and
chest X-ray should be done at 3 months and again at 1, 2 and 5
years [III, B]. The follow-up schedule is specific to this protocol.
Stages IIc–IV
There is general agreement that best treatment for stage IIc–IV
seminomas involves multiagent platinum-containing chemo-
therapy (usually BEP). There is evidence from a large prospective
randomised trial that three cycles of BEP is equivalent to four
cycles for good prognosis GCTs (de Wit et al, 2001).
Seminoma stage IIcþ follow-up With large volume seminoma, it
is not uncommon for there to be a residual mass following
chemotherapy. In most cases, this represents fibrotic scar tissue.
Attempted surgical removal can be difficult. In most cases, the
masses will resolve in time, but if larger than 3cm the chance of
active malignancy is higher (Puc et al, 1996). If PET scanning is
available, then data from De Santis et al (2004) suggests that 80%
of patients with active disease can be identified and should be
undertaken for masses 43cm. Following PET, we suggest
performing CT scans at regular intervals (6 monthly to annually)
until complete response or a stable calcified mass is the only
residuum. When this is achieved, the low rate of relapse makes
further scanning unnecessary [III, B]. The follow-up schedule for
advanced seminoma is the same as for NSGCT, but patients can be
discharged after 5 years if free of relapse (Shahidi et al, 2002).
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sNONSEMINOMA
Stage I
The options for men with stage I NSGCTs (post orchidectomy) are
close surveillance or adjuvant chemotherapy (in the form of two
cycles of BEP chemotherapy). Adjuvant primary retroperitoneal
lymph node dissection (RPLND) is rarely performed within the
United Kingdom, but we present a discussion of the pertinent
issues.
NS stage I surveillance Retrospective series identified the
histological presence of vascular invasion as the strongest
predictor of relapse in stage I NSGCTs (Freedman et al, 1987;
Vergouwe et al, 2003). Surveillance as a strategy for the manage-
ment of stage I tumours was prospectively studied by the Medical
Research Council and their results were published in 1992 (Read
et al, 1992). In the absence of high-risk features where relapse rates
approach 50%, among the usual population undergoing surveil-
lance a relapse rate of around 20% is to be expected. Surveillance
protocols should, therefore, be directed at promptly detecting
these relapses, as with treatment at this stage disease-free survival
rates of 98% should be achieved.
It is clear from a number of series that the vast majority of
relapses will occur within 2 years, most in the first year of
surveillance. In the original prospective study, 80% (of 100
relapses) occurred within the first year (54 of these in the first 6
months) and 92% by 2 years (Read et al, 1992). A number of
subsequent studies have demonstrated similar results and are
summarised in Table 1. A series of 478 patients (stage I NSGCT)
undergoing surveillance at the Royal Marsden Hospitals (Royal
Marsden, unpublished data) with a relapse rate of 24% showed
almost identical results with 80% of relapses occurring within 1
year, 90% within 2 years, 94% by 3 years and 97% by 4 years. The
subsequent relapses occurred at 6 years (one patient) and 7 years
(two patients).
The site and subsequent detection of relapse was assessed in our
Royal Marsden series. 72/111 (67%) were marker positive and in 58
(51%) this was the flag. In 15 (14%) this was the only detectable
abnormality. Sixty-two patients (56%) had evidence of retro-
peritoneal adenopathy, and in 55 (50%) this was the only
anatomical site of relapse. Of these, 18 (16%) were marker
negative, making cross-sectional abdominal imaging mandatory in
surveillance protocols. Thoracic relapse rates of around 20% can
be expected but methods of detection remain controversial,
predominantly as drawing conclusions from small series is
unreliable. From a series of 168 patients, 8/42 relapses (19%)
occurred within the chest (Harvey et al, 2002), although 7 had
other indicators of relapse (raised markers and abnormal
abdominopelvic CT scans) and all 8 had abnormal chest radio-
graphs, and the authors concluded that there is no requirement for
thoracic CT. Some may go further – of 170 patients undergoing
surveillance for stage I NS, all recurrences were detected with
clinical history and examination, markers and abdominopelvic CT,
and it was felt that the omission of chest radiographs would not
have altered the outcome (Sharir et al, 1999). However, of the 111
Royal Marsden patients who experienced relapse, there were 8
(7%) in whom CT scans of the thorax, performed on the
surveillance protocol, were the only detector of relapse.
Our suggested protocols then focus on the first year with
investigations reducing in intensity in subsequent years. The
patients have markers checked monthly for the first year, with
2-monthly chest X-rays and clinical examination [III, B] and CT
scans (abdomen only unless pelvis deemed high risk) at 3 months
and 1 year [I, A]. This is broadly similar to the recent NCCN
Guidelines, although reduces the frequency of CT, as supported by
data from the recently presented MRC TE08 trial, where a two-scan
strategy was no less effective than performing five scans
(Kondagunta et al, 2003; Rustin et al, 2007). From the above data,
it is clear that relapse after 5 years is so infrequent as to merit
discharge at this point. Given the increasing awareness of long-
term side effects, we also advocate assessing cardiovascular risk
factors in these untreated control patients at 2 and 5 years [III, B].
NS stage I post-adjuvant chemotherapy follow-up Patients in
whom the rate of relapse is expected to approach 50% (ie,
possessing high-risk features, predominately vascular invasion)
are also candidates for surveillance as treatment at relapse confers
identical long-term survival outcomes, but may also be offered
adjuvant chemotherapy, most commonly in the form of two cycles
of BEP. This has been shown to reduce the rate of relapse to o5%
(Cullen et al, 1996). The proven GCT relapses seen in this trial
occurred after 7 months and were detected by raised markers, and
a published review including 148 patients treated with adjuvant
chemotherapy demonstrated six (4%) relapses, all within 2 years of
treatment (Oliver et al, 2004).
Reflecting both this much reduced rate of relapse and the
conserved tendency to early presentation of recurrence, our
protocol reduces the frequency of investigation and follow-up
visit at an earlier stage than the previously described for
surveillance [III, B]. We suggest one scan of abdomen be
performed at 6 months as occasionally a microscopically involved
lymph node may increase in size due to the presence of teratoma
differentiated [V, D]. As treatment has been administered,
assessment of late effects is increasingly important, our protocols
assess this at 2 and 5 years post treatment [III, B], but lifelong
awareness of the risk of treatment-related effects is important.
NS stage I post-adjuvant retroperitoneal lymph node dissection
follow-up Adjuvant RPLND allows more accurate histopatholo-
gical staging of patients with around 30% of patients deemed stage
I by conventional radiological and marker evaluation having
pathological evidence of nodal metastases (ie, stage II) at surgery.
Such patients are typically offered ‘adjuvant’ chemotherapy in the
form of two cycles of BEP with subsequent recurrences uncommon
indeed (Donohue et al, 1993; Spermon et al, 2002; Albers et al,
2003). Patients without evidence of nodal metastases demonstrate
relapse rates between 10 and 13%, the vast majority of which are
pulmonary in nature and occur within the first year.
We would advocate following up patients treated with RPLND
and two cycles of BEP (ie, node positive) as post-adjuvant
chemotherapy (above). Around 30% node-positive patients not
receiving further treatment relapse (Donohue et al, 1993) and as
such should be followed up along the NS stage I surveillance
protocol, as should node-negative patients, although abdominal
relapse post-RPLND should be uncommon.
Stage II–IV NSGCT
Germ cell tumours are one of the rare instances where the majority
of patients with disseminated disease can be cured, predominately
Table 1 Time course of relapse in surveillance of stage I nonseminoma
Cumulative relapses
Reference Patients Relapses
Year
1( % )
Year
2(%)
Year
3(%)
MRC, Read et al (1992) 373 100 (27%) 80 92 100
Atsu et al (2003) 132 32 (24%) 87 100 100
Daugaard et al (2003) 301 86 (29%) 80 89 95
Divrik et al (2006) 211 66 (31%) 79 95 —
Drury A Royal Marsden,
unpublished)
478 115 (24%) 80 90 97
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swith combination chemotherapy, although often requiring surgery
(and less frequently radiotherapy) to eradicate residual disease.
Overall, around 80% should achieve complete clinical þ/ 
radiological response to treatment (depending upon IGCCCG
prognostic factors) (Mead et al, 1992; Sonneveld et al, 2001;
Horwich et al, 2006). Radiological assessment of response
continues until residual disease has either been surgically resected
or completely resolved, with a CT scan performed at this point as a
baseline for follow-up.
Disseminated disease (NS/seminoma), post-curative treatment
follow-up Once curative treatment (CR) has been achieved and
treatment completed, relapse rates of up to 10% might be expected.
The majority of these will occur within the first year, although a
late relapse rate (that occurring 42 years post completion of
treatment) of around 3% is observed (Gietema et al, 2002; Ronnen
et al, 2005). Of 353 patients treated in the Netherlands between
1977 and 1999, 290 (82%) achieved CR following cisplatin-based
chemotherapy and surgery as required. Thirty-three of these (11%)
subsequently relapsed, with a median time to relapse of 17 months
(range: 6–179). In 27 (81%) of these, elevated markers ‘flagged’ the
relapse, and a further 4 markers corresponded to recurrence found
at physical examination. Two patients with brain metastasis
presented with neurological symptoms. In no patients did the
chest radiograph assist with detection of recurrence, and the
authors point out that following ESMO Guidelines would have
resulted in over 6000 X-rays in total for this period (Gietema et al,
1992).
Specifically regarding late recurrences (Ronnen et al, 2005), 17/
551 patients relapsed after at least 2 years post chemotherapy, with
a median time to relapse of 7.8 years (range: 2.7–18.7) and 9/17
presenting with clinical symptoms of recurrence. In all, 3 out of the
17 presented with raised markers (although a further 9 subse-
quently demonstrated raised markers), and, in this series, two
relapses were detected by abnormal chest X-ray. From a retro-
spective review of 1263 patients with TGCT treated at the Royal
Marsden Hospital (513 with metastatic NSGCT), 53 had recur-
rences after 2 years, 14 of which occurred later than 5 years (9/14
detected at routine annual follow-up and 5 presenting with interval
symptoms). Twelve of these very late recurrences were in patients
treated for metastatic NS (giving an annual risk of recurrence in
these patients of 1% between 5 and 10 years) (Shahidi et al, 2002).
Our protocols therefore utilise less imaging, although in the
absence of randomised data we continue to recommend 4-monthly
chest X-rays for the first 2 years, but annually after that [III, B].
Markers are checked 2 monthly for the first year, 4 monthly for the
second and 6 monthly after that [III, B] for up to 5 years. The
continued risk of late relapse in NS patients means that we
recommend continuing to follow up these patients annually from 5
to 10 years and every 2 years subsequently [V, D]. Late relapse is
rare (Shahidi et al, 2002) in metastatic seminoma so would
routinely discharge seminoma patients at 5 years [III, B].
ASSESSING LATE TOXICITY
Although a thorough discussion regarding long-term side effects
of treatment is beyond the scope of this article, a growing body of
data demonstrates that survivors of TGCTs are at increased risk of
hypogonadism, and a metabolic syndrome including obesity,
hypertension, diabetes and hypercholesterolaemia (Vaughn et al,
2002). We, therefore, include in our protocols assessing patients
for these features patients at 2, 5 and 10 years. We would assess BP,
glucose, fasting cholesterol, LH and testosterone at these time
points. Patients should be advised not to smoke and to be
counselled regarding weight gain. A history of cardiac disease or
other health problems should be sought particularly beyond 5
years of follow-up. It is not known if other screening tests for
coronary artery disease or for secondary cancer would be
advantageous, but patients should be encouraged to avail
themselves of any relevant national screening programmes such
as the one being developed for colorectal cancer.
CONCLUSIONS
Managing patients with TGCTs is a complex business requiring
multidisciplinary teamwork and multiple clinical scenarios. While
evidence for best practice in terms of treatment is widely available
and continuously evolving, the important issues regarding follow-
up schedule are for the most part left to individual preference. The
standardising of follow-up would result in optimising risk/benefit
ratios for individual patients, while ensuring economic use of
resources. Furthermore, this should enable future trials to address
specific issues around follow-up giving meaningful and useful
results.
These guidelines have been adopted by the South East England
Testicular Cancer supraregional network.
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sAPPENDIX A
Seminoma: Stage 1. Surveillance
Markers:AFP, HCG and LDH
Year 1
Month 1 2345678 91 0 1 1 1 2
Clinical xxxx
Markers xxxx
CXR xx
CT xx
Year 2 Late effects(∗)
Month 1 2345678 91 0 1 1 1 2
Clinical xxxx
Markers x xxx
CXR x x
CT x x
Year 3
Month 1 234567891 0 1 1 1 2
Clinical xxx
Markers xxx
CXR x
CT x
Year 4
Month 1 2345678 91 0 1 1 1 2
Clinical  xx
Markers xx
CXR x
CT x
Year 5 Late effects(∗)
Month 1 234567891 0 1 1 1 2
Clinical  xx
Markers x x
CXR x
CT x
Annual follow-up until 10 years, clinical and markers 
Seminoma: Stage 1. Single-agent carboplatin
Markers: AFP, HCG and LDH
Year 1 
Month  1234567891 0 1 1 1 2
Clinical  xx x x x
Markers xx x x x
CXR  xx
CT x
Year 2                      Late effects(∗)
Month  1234567891 0 1 1 1 2
Clinical  xxx
Markers xxx
CXR  x
CT x
Year 3 
Month  1234567891 0 1 1 1 2
Clinical  xx
Markers x x
CXR  x
CT
Year 4 
Month  1234567891 0 1 1 1 2
Clinical  xx
Markers xx
CXR  x
CT
Year 5                                            Late effects(∗)
Month  1 2 34567 8910 11 12
Clinical  xx
Markers xx
CXR  x
CT x
Annual follow-up until 10 years, clinical and markers 
Seminoma: Stage 1. Para-aortic RT
Markers: AFP, HCG and LDH  
Year 1 
Month  1 2 3 4 5 6 7 8 9 10 11 12 
Clinic  x xxx
Markers  xxxx
CXR xx x
CT x
Year 2                                            
Month  1 2 3456789 10 11 12 
Clinic  x xx
Markers  x xx
CXR x
CT x
Year 3 
Month  123456789 10 11 12 
Clinic  xx
Markers  xx
CXR x
CT
Year 4 
Month  1 2 3 4 5 6 7 8 9 10 11 12 
Clinic  xx
Markers  xx
CXR x
CT
Year 5                                            
Month  1 2 3 4 5 6 7 8 9 10 11 12 
Clinic  xx
Markers  xx
CXR x
CT x
Discharge after 5 years 
Seminoma: Stages IIa/b. Carboplatin and radiotherapy
Year 1 
Month  1 2 3 4 5 6 7 8 9 10 11 12 
Clinical  xxxx
Markers xxxx
CXR  xx x
CT  xx
Year 2                                            
Month  1 2 3 456 7 891 0  1 1 12 
Clinical  xxx
Markers x x x
CXR  x
CT  x
Year 3 
Month  1 2 3 4 5 6 7 8 9 10 11 12 
Clinical  xx
Markers xx
CXR  x
CT 
Year 4 
Month  1234 5 6 7 8 9 10 11 12 
Clinical  xx
Markers x x
CXR  x
CT 
Year 5                                         
Month  1 2 3 4 5 6 7 8 9 10 11 12 
Clinical  xx
Markers xx
CXR  x
CT  x
Annual follow-up until 10 years, clinical and markers 
Markers: AFP, HCG and LDH  
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sNonseminoma germ cell tumour: Stage 1. Surveillance
CT scans should be of abdomen only unless pelvis at high risk 
Late effects should be assessed at 2 and 5 years (See Late effects box)∗
Year 1
Month 1 2 3 4 5 6 7 8 9 10 11 12
Clinical x x x x x x x
Markers x x x x x x x x x x x x
CXR x x x x x x x
CT abdo x x
Year 2 Late effects(∗)
Month 1 2 3 4 5 6 7 8 9 10 11 12
Clinical x x x x
Markers x x x x
CXR x x x x
CT abdo x
Year 3
Month 1 2 3 4 5 6 7 8 9 10 11 12
Clinical x x x
Markers x x x
CXR x x x
CT
Year 4
Month 1 2 3 4 5 6 7 8 9 10 11 12
Clinical x x
Markers x x
CXR x x
CT
Year 5 Late effects(∗)
Month 1 2 3 4 5 6 7 8 9 10 11 12
Clinical x x
Markers x x
CXR x x
CT
Markers: AFP,  HCG and LDH
Nonseminoma germ cell tumour: Stage 1. Adjuvant 
chemotherapy
CT scan should be of abdomen only unless pelvis at high risk 
Late effects should be assessed at 2 and 5 years (See Late effects box)∗
Year 1
Month 1 2 3 4 5 6 7 8 9 10 11 12
Clinical x x x x x
Markers x x x x x
CXR x x x
CT abdo x
Year 2  Late effects(∗)
Month 1 2 3 4 5 6 7 8 9 10 11 12
Clinical x x x
Markers x x x
CXR x
CT
Year 3
Month 1 2 3 4 5 6 7 8 9 10 11 12
Clinical x x
Markers x x
CXR x
CT
Year 4
Month 1 2 3 4 5 6 7 8 9 10 11 12
Clinical x x
Markers x x
CXR x
CT
Year 5  Late effects(∗)
Month 1 2 3 4 5 6 7 8 9 10 11 12
Clinical x x
Markers x x
CXR x
CT
Markers: AFP, HCG and LDH
Markers: AFP, HCG and LDH
CT until CR with or without surgery, frequency determined by MDT 
Late effects should be assessed at 2,5 and 10 years (See Late effects box)∗
Year 1
Month 1 2 3 4 5 6 7 8 9 10 11 12
Clinical xxxxxx
Markers xxxxxx
CXR xxx
CT
Year 2  Late effects(∗)
Month 1 2 3 4 5 6 7 8 9 10 11 12
Clinical xxx  
Markers xxx
CXR xxx
CT
Year 3
Month 1 2 3 4 5 6 7 8 9 10 11 12
Clinical xx
Markers xx
CXR x
CT
Year 4
Month 1 2 3 4 5 6 7 8 9 10 11 12
Clinical xx
Markers xx
CXR x
CT
Year 5 Late effects(∗)
Month 1 2 3 4 5 6 7 8 9 10 11 12
Clinical xx
Markers xx
CXR x
CT x
Discharge seminoma patients at 5 years
For NSGCT patients, follow up annually until 10 years and then 
biannually. Stop performing CXRs at 10 years
(∗)  Late effects  
Clinical examination including blood pressure measurement,  
height and weight  
 
Urea + electrolytes, fasting cholesterol (HDL and LDL), trigylcerides, 
fasting glucose 
Hormone profile (FSH, LH and testosterone) 
NSGCT and seminoma: Stages IIc–IV. Post chemotherapy
APPENDIX B
Levels of evidence and grading of recommendation
Level Type of evidence
I Evidence is obtained from meta-analysis of multiple, well-
designed, controlled studies. Randomised trials with low
false-positive and low false-negative errors (high power).
II Evidence is obtained from at least one well-designed
experimental study. Randomised trials with high false-
positive and/or negative errors (low power).
III Evidence is obtained from well-designed, quasi-experimen-
tal studies such as nonrandomised, controlled single-group,
pre–post, cohort, time or matched case–control series.
IV Evidence is from well-designed, nonexperimental studies such
as comparative and correlational descriptive and case studies.
V Evidence is from case reports and clinical examples.
Grade Grading of recommendation
A There is evidence of type I or consistent findings from
multiple studies of types II, III or IV.
B There is evidence of types II, III or IV and findings are
generally consistent.
C There is evidence of types II, III or IV but findings are
inconsistent.
D There is little or no systematic empirical evidence.
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